A Bone-Derived Brake on Bone Marrow’s Destructive Cells
A recent study in Experimental & Molecular Medicine reveals a novel molecular pathway regulating osteoclastogenesis, the process central to bone resorption in conditions like osteoporosis. Researchers identified that osteomodulin (OMD), a protein secreted by bone-forming osteoblasts, is significantly reduced in patients with osteoporosis. Using genetic models, they demonstrated that OMD deficiency leads to accelerated bone loss and increased osteoclast activity. The mechanism involves OMD binding to the integrin receptor ITGB8 on osteoclast precursors, which subsequently downregulates ribonucleotide reductase M2 (RRM2). This interaction impairs mitochondrial respiration and ATP production within these precursor cells, effectively restraining their differentiation into mature, bone-resorbing osteoclasts. This discovery positions OMD as a crucial endogenous regulator of bone marrow microenvironment and hematopoietic cell function.
Study Significance: For hematologists and researchers focused on bone marrow disorders and the hematopoietic niche, this finding bridges bone biology and marrow function. It identifies OMD as a potential therapeutic target for osteoporosis, suggesting that boosting its levels or mimicking its action could offer a new strategy to protect bone integrity. This research underscores the critical cross-talk between bone stromal cells and marrow-resident hematopoietic lineages, offering fresh insights for managing diseases where bone and blood homeostasis are intertwined.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
